The Preeclampsia Foundation is pleased to announce the recipients of our annual volunteer recognition awards. The Foundation's volunteer program features three award categories to reflect the growing nature of its volunteer program, which now includes more than 800 active volunteers across the country.

"We're so pleased to recognize our exceptional volunteers, especially those who exemplify our core values," said Director of Community Relations Laney Poye. "We couldn't have made the strides we've made in awareness, education, and research without the dedication of many talented individuals."

The 2015 recipients are:

A study published on January 7, 2016, in the New England Journal of Medicine by a consortium of European investigators [Zeisler et al, NEJM 2016;374:13-22] heralded the predictive value of a blood test in women suspected of preeclampsia. This test is currently available in most of the world, but not in the United States. According to Jim Harris, Director of Medical Affairs at Roche Diagnostics, the manufacturer, "Roche's assay is in development for the U.S., but is not yet available for routine clinical use. It will have to be approved by the FDA first."

The Preeclampsia Foundation extends a warm welcome to  AMAG Pharmaceuticals as its newest Corporate Advisory Council member.

"Our Corporate Advisory Council  members are invaluable in helping us advance our shared mission of awareness, education, research, advocacy, and support for those affected by preeclampsia and related hypertensive disorders of pregnancy," said Eleni Tsigas, the Foundation's Executive Director.

AMAG Pharmaceuticals uses its business and clinical expertise to develop and commercialize products that provide clear benefits and improve people's lives. Based in Waltham, Massachusetts, AMAG has a diverse portfolio of products in the areas of maternal health, anemia management, and cancer supportive care. AMAG continues to work to expand the impact of these and future products for patients by delivering on its growth strategy, which includes organic growth, as well as the pursuit of products and companies that align with AMAG's existing therapeutic areas or those that could benefit from its proven core competencies. For additional company information, please visit www.amagpharma.com.

Several preeclampsia researchers are collaborating with rEVO Biologics, a company developing a treatment for preeclampsia, to better understand the patient's journey through diagnosis, management, treatment, and delivery -- not necessarily in that order! Analyzing thousands of real-world patient experiences will help us to develop better education tools and processes, and to advocate to healthcare providers for improved patient engagement. This survey is being administered by The Preeclampsia Registry, a service of the Preeclampsia Foundation.

Only those who completed their first enrollment questionnaire to The Preeclampsia Registry will be eligible to take this survey. If you haven't finished your questionnaire, simply log-in to the Registry at www.preeclampsiaregistry.org and select "Finish a Questionnaire that I Started" from your MyRegistry page.